Cardiac Nestin + Mesenchymal Stromal Cells Enhance Healing of Ischemic Heart Through Periostin-Mediated M2 Macrophage Polarization
Yan Liao,Guilan Li,Xiaoran Zhang,Weijun Huang,Dongmei Xie,Gang Dai,Shuanghua Zhu,Dihan Lu,Zhongyuan Zhang,Junyi Lin,Bingyuan Wu,Wanwen Lin,Yang Chen,Zhihong Chen,Chaoquan Peng,Maosheng Wang,Xinxin Chen,Mei Hua Jiang,Andy Peng Xiang
DOI: https://doi.org/10.1016/j.ymthe.2020.01.011
IF: 12.91
2020-01-01
Molecular Therapy
Abstract:Mesenchymal stromal cells (MSCs) show potential for treating cardiovascular diseases, but their therapeutic efficacy exhibits significant heterogeneity depending on the tissue of origin. This study sought to identify an optimal source of MSCs for cardiovascular disease therapy. We demonstrated that Nestin was a suitable marker for cardiac MSCs (Nes(+)cMSCs), which were identified by their self-renewal ability, tri-lineage differentiation potential, and expression of MSC markers. Furthermore, compared with bone marrow-derived MSCs (Nes(+)bmMSCs) or saline-treatedmyocardial infarction (MI) controls, intramyocardial injection of Nes(+)cMSCs significantly improved cardiac function and decreased infarct size after acute MI (AMI) through paracrine actions, rather than transdifferentiation into cardiac cells in infarcted heart. We further revealed that Nes(+)cMSC treatment notably reduced pan-macrophage infiltration while inducingmacrophages toward an anti-inflammatory M2 phenotype in ischemic myocardium. Interestingly, Periostin, which was highly expressed in Nes(+)cMSCs, could promote the polarization of M2-subtypemacrophages, and knockdown or neutralization of Periostin remarkably reduced the therapeutic effects of Nes(+)cMSCs by decreasing M2 macrophages at lesion sites. Thus, the present work systemically shows that Nes(+)cMSCs have greater efficacy than do Nes(+)bmMSCs for cardiac healing after AMI, and that this occurs at least partly through Periostin-mediated M2 macrophage polarization.